Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Why It Matters

Missing the primary endpoint raises doubts about Biogen’s tau‑targeted Alzheimer’s strategy, yet biomarker gains and strong Leqembi sales keep the franchise financially resilient. Technical support at the 50‑day SMA suggests a buying opportunity for investors betting on future approvals.

Key Takeaways

• Diranersen missed primary endpoint in Phase 2 CELIA trial
• Biomarker data showed robust tau reduction across all doses
• Lowest 60‑mg dose slowed clinical decline most noticeably
• Leqembi sales rose 74% to $168 million YoY
• Analysts see 50‑day SMA near $185 as buying zone

Pulse Analysis

The biotech sector thrives on high‑risk, high‑reward narratives, and Alzheimer’s remains a marquee target. While amyloid‑focused drugs dominate headlines, tau‑targeted approaches like Biogen’s antisense oligonucleotide diranersen address a protein directly linked to neuronal degeneration. Investors watch these programs closely because a successful tau therapy could complement existing amyloid treatments, opening a pathway to combination regimens that may finally alter disease progression.

Biogen’s CELIA readout delivered a mixed signal: the primary clinical endpoint was missed, but the trial produced compelling biomarker data. Across all dose levels, cerebrospinal‑fluid tau and PET‑measured tau pathology fell significantly, indicating the drug engages its intended target. Notably, the lowest 60‑mg dose produced the most consistent slowing of cognitive decline, a nuance that may guide dose‑selection for future Phase 3 work. Regulators increasingly value biomarker proof‑of‑concept, so these results keep the tau franchise alive despite the statistical miss.

Financially, Biogen’s outlook is anchored by Leqembi, whose sales surged 74% to $168 million, reinforcing the company’s cash flow while the FDA reviews an expanded subcutaneous formulation. The pending $41‑per‑share acquisition of Apellis adds rare‑disease and immunology products, diversifying revenue streams. Technically, the stock hovers just above its 50‑day simple moving average near $185, a level that many traders view as a support zone. With the MACD showing short‑term weakness but no fundamental red flags, disciplined investors may view the dip as a strategic entry point ahead of potential future approvals.